Kvindelige patienter i kliniske studier viste sig at være mere modtagelige end mandlige patienter med hensyn til gastrointestinale bivirkninger og vægttab.
Female patients in clinical studies were found to be more susceptible than male patients to gastrointestinal adverse reactions and weight loss.